2016
DOI: 10.1001/jamacardio.2016.2225
|View full text |Cite
|
Sign up to set email alerts
|

Adult Stem Cell Therapy and Heart Failure, 2000 to 2016

Abstract: Importance Stem cell therapy is a promising treatment strategy for patients with heart failure, which accounts for over 10% of deaths in the U.S. annually. Despite over a decade of research, further investigation is still needed to determine whether stem cell regenerative therapy is clinically effective and can be routinely implemented in clinical practice. Objective The purpose of this review is to describe the current progress in cardiac stem cell regenerative therapy using adult stem cells and highlight t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
211
0
7

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 266 publications
(219 citation statements)
references
References 75 publications
1
211
0
7
Order By: Relevance
“…5 We expect that cell therapy in children, however, will be much more successful. In fact, the young may be the best responders because their myocardium is inherently more pliable and will respond more vigorously to the biological cues of the transplanted cells.…”
Section: Best Responders To Cell Therapy May Be Childrenmentioning
confidence: 99%
“…5 We expect that cell therapy in children, however, will be much more successful. In fact, the young may be the best responders because their myocardium is inherently more pliable and will respond more vigorously to the biological cues of the transplanted cells.…”
Section: Best Responders To Cell Therapy May Be Childrenmentioning
confidence: 99%
“…To identify pro-survival components for use in our biomaterial to treat ischaemic injury, we evaluated a selection of growth factors on the basis of previous studies from our laboratory and others (see Supplementary Table 1) 911 . For initial screening, bone marrow mononuclear cells (BMMNCs) were used, given their prevalence in clinical trials and their potential applications to human patients 12 . BMMNCs were harvested from transgenic L2G mice, which constitutively express the firefly luciferase (FLuc) and green fluorescence protein (GFP) reporter genes driven by the β-actin promoter, as previously described (Supplementary Fig.…”
mentioning
confidence: 99%
“…Moreover, a growing number of phase I and II clinical trials have proven the feasibility and safety of SC application [381]. However, data from human studies addressing functional improvement are inconsistent.…”
Section: Improvement Strategies Of Sc-based Therapiesmentioning
confidence: 99%